Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

" "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, including the results of the trials for Adlea, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Anesiva, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended

March 31,

2008 2007

(unaudited) (unaudited)

Contract revenue
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
(Date:1/14/2014)... Park, NC (PRWEB) January 14, 2014 ... focusing on ultra-sensitive POC diagnostic platforms and novel disease specific ... first round of financing netting a total of $690,000. The ... equity capital in the company. This group of private investors ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" ... of nutrients for plants and,animals in the People,s ... a conference call at 8:00 a.m. Eastern Time ... the quarter ended June 30, 2008., To ...
... Massachusetts, August 13, Shire Limited (LSE: SHP, NASDAQ: ... since July,3, 2008 it has acquired 81% of ... indirect subsidiary Shire Deutschland Investments GmbH (formerly Maia,Elfte ... respect of the remaining outstanding shares in Jerini., ...
... Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets of Spherics, ... all pharmaceutical,intellectual property will be sold at a sealed ... pieces of intellectual property for sale is its lead,product, ... currently has,more than $2 billion in sales despite twice ...
Cached Biology Technology:Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results 2Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document 2Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document 3
(Date:7/9/2014)... selection for traits that are attractive to the opposite ... to mate, the tail of male peacocks being an ... Riverside have now found that sexual selection and "placentation" ... Describing the life histories of more than 150 species ... that species with placentas tend to have males that ...
(Date:7/9/2014)... A crucial piece of the puzzle behind nature,s ... that could help advance the development of artificial ... been provided by an international collaboration of scientists ... Laboratory (Berkeley Lab) and the SLAC National Accelerator ... Light Source (LCLS), the world,s most powerful x-ray ...
(Date:7/9/2014)... Researchers studying critically ill children with traumatic injuries ... patients are likely to develop a hospital-acquired infection. ... Hospital and published online in June in the ... larger efforts that could lead to the clinical ... to prevent or reverse immune system damage following ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... 19, 2009Scientists say they are forging ahead in developing ... renewable while having a minimal impact on the environment, ... A consensus is emerging that no one technology will ... novel methodologies will contribute to meeting biofuel needs, according ...
... Swiss Institute of Bioinformatics today announced the winners of the ... Award at the 7th annual [BC]2 Basel Computational Biology Conference. ... The winner of the 2009 SIB Young Bioinformatician Award is ... the past four years with the SIB in the Bioinformatics ...
... of Cordell Bank National Marine Sanctuary indicates that the ... is fair to good, but identifies several emerging threats ... as marine debris, ocean acidification and invasive species have ... said Dan Howard, sanctuary superintendent. "This report provides a ...
Cached Biology News:The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3NOAA report finds threats to California's Cordell Bank Marine Sanctuary 2